Your browser doesn't support javascript.
loading
Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy.
Mizukami, Takuro; Takahashi, Masaki; Sunakawa, Yu; Yuki, Satoshi; Kagawa, Yoshinori; Takashima, Atsuo; Kato, Kyoko; Hara, Hiroki; Denda, Tadamichi; Yamamoto, Yoshiyuki; Shiozawa, Manabu; Oki, Eiji; Okamoto, Wataru; Yoshino, Takayuki; Eguchi Nakajima, Takako.
Afiliación
  • Mizukami T; Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.
  • Takahashi M; Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan.
  • Sunakawa Y; Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.
  • Yuki S; Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan.
  • Kagawa Y; Department of Surgery, Osaka Prefectural General Medical Center, Osaka, Japan.
  • Takashima A; Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Kato K; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Hara H; Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan.
  • Denda T; Gastroenterology, Chiba Cancer Center, Chiba, Japan.
  • Yamamoto Y; Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
  • Shiozawa M; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
  • Oki E; Department of Surgery and Science, Kyushu University, Fukuoka, Japan.
  • Okamoto W; Cancer Treatment Center, Hiroshima University Hospital, Hiroshima, Japan.
  • Yoshino T; Translational Research Support Section, National Cancer Center Hospital East, Kashiwa, Japan.
  • Eguchi Nakajima T; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Target Oncol ; 17(3): 343-353, 2022 05.
Article en En | MEDLINE | ID: mdl-35524872
BACKGROUND: Primary tumor site and genomic status are utilized for regimen selection in metastatic colorectal cancer; however, the impact on clinical practice is not well known. OBJECTIVE: We aimed to clarify the impact of primary tumor site and genomic status on clinical practice in metastatic colorectal cancer. METHODS: The relationship between primary tumor site, genomic alterations, and clinical outcomes was evaluated in patients with untreated metastatic colorectal cancer using real-world data of a prospective observational study, SCRUM-Japan GI-SCREEN with clinical and genomic data set in 1011 patients enrolled from February 2015 to March 2017. RESULTS: Five hundred and sixty-one patients were eligible for this study. Patients with right-sided tumors had a significantly worse survival, left-sided tumors with wild-type RAS had favorable outcomes when treated with anti-epidermal growth factor receptor monoclonal antibodies, and cecum tumors had poor prognosis when treated with bevacizumab. The rate of gene alterations varied considerably depending on the primary site. In addition, gene alterations of KRAS, BRAF, SMAD4, or TP53 had individually different contributions to survival from site to site. KRAS, BRAF, PTEN, or SMAD4 mutations were associated with efficacy of bevacizumab or anti-epidermal growth factor receptor monoclonal antibodies. CONCLUSIONS: Primary tumor site is a clinically useful biomarker to predict survival in patients with metastatic colorectal cancer treated with first-line chemotherapy. Moreover, the prognostic or predictive value of several gene alterations by primary tumor site should be considered in clinical practice.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Neoplasias del Colon / Antineoplásicos Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Target Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Francia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Neoplasias del Colon / Antineoplásicos Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Target Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Francia